Moorthy VS - Search Results

1

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.

Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, Schneider J, Hannan C, Roy M, Gilbert SC, Peto TE, Hill AV. Moorthy VS, et al. Vaccine. 2003 May 16;21(17-18):1995-2002. doi: 10.1016/s0264-410x(02)00771-5. Vaccine. 2003. PMID: 12706689

2

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. McConkey SJ, et al. Among authors: moorthy vs. Nat Med. 2003 Jun;9(6):729-35. doi: 10.1038/nm881. Epub 2003 May 25. Nat Med. 2003. PMID: 12766765 Clinical Trial.

3

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV. Gilbert SC, et al. Among authors: moorthy vs. Vaccine. 2006 May 22;24(21):4554-61. doi: 10.1016/j.vaccine.2005.08.048. Epub 2005 Aug 24. Vaccine. 2006. PMID: 16150517 Review.

4

Malaria vaccines.

Moorthy V, Hill AV. Moorthy V, et al. Br Med Bull. 2002;62:59-72. doi: 10.1093/bmb/62.1.59. Br Med Bull. 2002. PMID: 12176850 Review.

5

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.

Hill AV, Reece W, Gothard P, Moorthy V, Roberts M, Flanagan K, Plebanski M, Hannan C, Hu JT, Anderson R, Degano P, Schneider J, Prieur E, Sheu E, Gilbert SC. Hill AV, et al. Dev Biol (Basel). 2000;104:171-9. Dev Biol (Basel). 2000. PMID: 11713817 Review.

6

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.

Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, Hannan C, Bojang K, McAdam KP, Schneider J, Gilbert S, Hill AV. Moorthy VS, et al. J Infect Dis. 2003 Oct 15;188(8):1239-44. doi: 10.1086/378515. Epub 2003 Sep 30. J Infect Dis. 2003. PMID: 14551895 Clinical Trial.

7

Malaria vaccine developments.

Moorthy VS, Good MF, Hill AV. Moorthy VS, et al. Lancet. 2004 Jan 10;363(9403):150-6. doi: 10.1016/S0140-6736(03)15267-1. Lancet. 2004. PMID: 14726170 Review.

8

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.

Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, Webster DP, Dunachie SJ, Moorthy VS, McConkey SJ, Gilbert SC, Hill AV. Keating SM, et al. Among authors: moorthy vs. J Immunol. 2005 Nov 1;175(9):5675-80. doi: 10.4049/jimmunol.175.9.5675. J Immunol. 2005. PMID: 16237057

9

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, Hill AV, Imoukhuede EB, Kumar S, Loucq C, Marsh K, Ockenhouse CF, Richie TL, Sauerwein RW. Moorthy VS, et al. Vaccine. 2009 Sep 25;27(42):5719-25. doi: 10.1016/j.vaccine.2009.07.049. Epub 2009 Aug 3. Vaccine. 2009. PMID: 19654061

10

MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives.

Moorthy VS, Reed Z, Smith PG; WHO Malaria Vaccine Advisory Committee. Moorthy VS, et al. Vaccine. 2009 Jan 29;27(5):624-8. doi: 10.1016/j.vaccine.2008.11.034. Epub 2008 Dec 4. Vaccine. 2009. PMID: 19061928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page